First-line afatinib in patients aged 75 or older with advanced non-squamous non-small cell lung cancer harboring EGFR mutations; non-randomized phase II trial

Next Previous
Trial Profile

First-line afatinib in patients aged 75 or older with advanced non-squamous non-small cell lung cancer harboring EGFR mutations; non-randomized phase II trial

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Dec 2017

At a glance

  • Drugs Afatinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 14 Dec 2017 Status changed from recruiting to active, no longer recruiting.
    • 12 Jun 2017 Status changed from not yet recruiting to recruiting.
    • 05 Aug 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top